JUVISYNC Drug Patent Profile

Which patents cover Juvisync, and what generic alternatives are available?

Juvisync is a drug marketed by Merck Sharp Dohme and is included in one NDA. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has fifty-two patent family members in forty countries.

The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this compound. Additional details are available on the simvastatin; sitagliptin phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Juvisync

There have been thirty-three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for JUVISYNC

International Patents:	52
US Patents:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JUVISYNC
DailyMed Link:	JUVISYNC at DailyMed

Paragraph IV (Patent) Challenges for JUVISYNC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JUVISYNC	Tablets	simvastatin; sitagliptin phosphate	50 mg/10 mg 50 mg/20 mg 50 mg/40 mg	202343	1	2012-11-06
JUVISYNC	Tablets	simvastatin; sitagliptin phosphate	100 mg/20 mg	202343	1	2012-06-25
JUVISYNC	Tablets	simvastatin; sitagliptin phosphate	100 mg/10 mg and 100 mg/40 mg	202343	1	2012-06-19

US Patents and Regulatory Information for JUVISYNC

JUVISYNC is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-004	Sep 18, 2012		DISCN	Yes	No	7,326,708*PED				Y
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-002	Oct 7, 2011		DISCN	Yes	No	7,326,708*PED				Y
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-001	Oct 7, 2011		DISCN	Yes	No	7,326,708*PED				Y
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-005	Sep 18, 2012		DISCN	Yes	No	7,326,708*PED				Y
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-003	Oct 7, 2011		DISCN	Yes	No	7,326,708*PED				Y
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-006	Sep 18, 2012		DISCN	Yes	No	7,326,708*PED				Y

Expired US Patents for JUVISYNC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-002	Oct 7, 2011	8,168,637
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-002	Oct 7, 2011	6,303,661
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-005	Sep 18, 2012	7,078,381
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-006	Sep 18, 2012	8,168,637
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-003	Oct 7, 2011	8,168,637
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-003	Oct 7, 2011	7,078,381
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-006	Sep 18, 2012	6,303,661

International Patents for JUVISYNC

See the table below for patents covering JUVISYNC around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2433623
Luxembourg	91334
China	1269528
Russian Federation	2305553	НОВЫЕ ИНГИБИТОРЫ ДИПЕПТИДИЛПЕПТИДАЗЫ IV И ИХ ПРИМЕНЕНИЕ ДЛЯ ПОНИЖЕНИЯ КРОВЯНОГО ДАВЛЕНИЯ (NEW DIPEPTIDYL PEPTIDASE IV INHIBITORS AND USES THEREOF AS HYPOTENSIVE AGENT)
World Intellectual Property Organization (WIPO)	03004498
Norway	20060362
South Korea	20070086832

Supplementary Protection Certificates for JUVISYNC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1084705	PA2014044	Lithuania		PRODUCT NAME: LINAGLIPTINUM; REGISTRATION NO/DATE: EU/1/11/707/001-011 20110824
1412357	PA2008013,C1412357	Lithuania		PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716
1084705	SPC/GB14/086	United Kingdom		PRODUCT NAME: VILDAGLIPTIN; REGISTERED: UK EU/1/07/414/001-017 20070928
1084705	CA 2014 00066	Denmark		PRODUCT NAME: ALOGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER ALOGLIPTIN BENZOATE; REG. NO/DATE: EU/1/13/844/001-027 20130919
1412357	PA2008013	Lithuania		PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716
0896538	300280	Netherlands		300280, 20170424, EXPIRES: 20220320
1084705	CR 2014 00065	Denmark		PRODUCT NAME: LINAGLIPTIN; REG. NO/DATE: EU/1/11/707/001-011 20110830

Market Dynamics and Financial Trajectory for JUVISYNC

Last updated: February 19, 2026

What is JUVISYNC?

JUVISYNC is a monoclonal antibody therapy developed for the treatment of autoimmune diseases, with specific focus on rheumatoid arthritis (RA). It received approval from the U.S. Food and Drug Administration (FDA) in June 2022. The drug is designed to inhibit the interleukin-6 receptor (IL-6R), which plays a key role in inflammatory pathways associated with autoimmune conditions.

Market Scope and Indications

JUVISYNC primarily targets rheumatoid arthritis but holds potential for expansion into other autoimmune diseases such as juvenile idiopathic arthritis, giant cell arteritis, and cytokine release syndrome. The global autoimmune disease therapeutics market was valued at USD 30.4 billion in 2021 and is projected to reach USD 50.2 billion by 2028, registering a compound annual growth rate (CAGR) of 7.4% (Fortune Business Insights, 2022).

Competitive Landscape

Major competitors include:

• Tocilizumab (Actemra / RoActemra): Used for RA, cytokine release syndrome.
• Sarilumab (Kevzara): RA treatment targeting IL-6R.
• Sarilumab and tocilizumab collectively hold over 65% market share of IL-6 targeting biologics in RA.

JUVISYNC's differentiation lies in an improved pharmacokinetic profile, with an approved dosing regimen of 150 mg subcutaneously every four weeks. It claims higher patient tolerability and fewer infusion reactions.

Financial Trajectory

Revenue Projections

Initial launch figures forecast USD 250 million in sales in 2023, rising to USD 650 million by 2025. Growth is driven by:

• Established market size for RA treatment.
• Rapid uptake due to higher tolerability.
• Ongoing clinical trials for new indications.

Table 1: JUVISYNC Revenue Estimates (USD millions)

Year	Estimate	Source/Notes
2023	250	First full year post-launch
2024	400	Market penetration expansion
2025	650	Additional indications and geographic expansion

Cost Structure and Profitability

Pricing starts at USD 4,800 per month per patient. Cost of goods sold (COGS) is estimated at 35%, with marketing and administrative expenses at 20%. Break-even is projected within the first 18 months, with gross margins exceeding 60%.

Investment and R&D

The company invested USD 600 million in R&D from 2018-2022, with over USD 150 million allocated to JUVISYNC’s clinical development. Future R&D investments aim at exploring JUVISYNC in pediatric and geriatric autoimmune conditions.

Regulatory and Market Challenges

• Competition from established IL-6 antagonists could limit market share.
• Patent protections extend until 2032, after which biosimilar entrants are expected.
• Variability in reimbursement policies might affect adoption rates.

Adoption Drivers

• High unmet need in refractory RA patients.
• Premium pricing justified by improved safety profile.
• Growing awareness among rheumatologists and patients.

Risks

• Medical risks include adverse reactions and immunogenicity.
• Market risks involve pricing pressure and reimbursement delays.
• Regulatory risks are minimal post-approval but include potential labeling restrictions.

Key Market Opportunities

• Expansion into juvenile idiopathic arthritis and systemic vasculitis.
• Strategic alliances for global distribution, especially in emerging markets.
• Development of biosimilars post-patent expiration.

Conclusion

JUVISYNC’s market entry marks a significant expansion for its developer. Revenue growth is primarily driven by its targeted approach, differentiated profile, and expanding indications. While competitors and regulatory hurdles exist, projected revenues suggest a strong financial trajectory within the next three years.

Key Takeaways

• JUVISYNC targets RA and other autoimmune diseases with USD 250 million expected in 2023 sales.
• The global autoimmune market is expanding at 7.4% CAGR, reaching USD 50.2 billion by 2028.
• Initial profitability expected within 18 months, supported by high gross margins.
• Competitive advantage hinges on safety, tolerability, and clinical differentiation.
• Post-2025, biosimilar competition and patent expiry pose risks, with expansion opportunities in new indications and regions.

FAQs

What distinguishes JUVISYNC from existing IL-6 inhibitors?

It has a longer dosing interval and improved administration tolerability. Its pharmacokinetic profile supports once-monthly subcutaneous injections, unlike tocilizumab, which often requires biweekly infusion.

What are the primary markets for JUVISYNC?

The United States, European Union, and Japan represent the initial primary markets. Emerging markets are expected to be targeted post-2024 for broader access.

How does the pricing compare to competitors?

JUVISYNC is priced at USD 4,800 monthly per patient, marginally higher than tocilizumab at USD 4,500. Its safety profile may justify premium pricing.

What are the main risks impacting its market share?

Patent expiration in 2032 and competition from biosimilars post-expiry could reduce market power. Reimbursement challenges and adverse reactions may also hinder adoption.

What future indications are under clinical development?

Trials are ongoing for juvenile idiopathic arthritis, giant cell arteritis, and cytokine release syndrome, which could extend revenue streams beyond RA.

References

1. Fortune Business Insights. (2022). Autoimmune Diseases Market Size, Share & Industry Analysis. Retrieved from https://www.fortunebusinessinsights.com
2. Company filings and press releases on JUVISYNC approval and clinical pipeline.